Adamis Pharmaceuticals Corporation
http://www.adamispharmaceuticals.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Adamis Pharmaceuticals Corporation
Asia Deal Watch: Aditum Bio Launches Vitalli To Develop Daewoong Immunology Candidate
In addition, deals involving Lupin/Medisol, Junshi/Dr. Reddy's, Zai Lab/MediLink, Kyowa Kirin/ADVANZ, Ipca/Unichem, Jiangsu Aidea/Kainos.
‘Clinically Meaningful Outcomes’ Data Urged For Long-Acting, Local Anesthetic Drug Products
Although a new FDA guidance recommends difference in pain scores as the primary efficacy endpoint for evaluation of postoperative analgesic effect, data on outcomes such as reduction in hospitalization and deaths from opioid abuse would be valuable and could provide a basis for inclusion in labeling; guidance is part of broader agency effort to reduce opioid use.
Alentis Adds To Bank Balance And Rides The Claudin Wave
While most of the R&D attention in the hot space of claudins has focused on targeting CLDN18.2, the Swiss biotech believes its CLDN1 programs have the advantage of a broader expression profile.
Chinese Biotechs Reshuffle Pipeline, Cut Headcount To Stay Afloat
Two bioventures in China have jettisoned immuno-oncology assets, including PD-1/L1- and CD47-targeting agents, while four other firms have disclosed shifts in R&D priorities and employee lay-offs as they deal with challenging conditions.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
-
- Biosyn Inc.
- Cellegy Holdings Inc
- DMK Pharmaceuticals Corp.
- US Compounding, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice